Market footprint Red Chip serves 18 Hemophilia Treatment Centers across 11 states and holds pharmacy licenses in all 50 states, indicating wide distribution channels and potential cross-sell opportunities to HTCs and manufacturers of high-cost drugs.

Outpatient focus Specializes in 340B outpatient factor programs and high-cost prescription management, suggesting opportunities to expand billing, collections, and compliance services for hospitals and chronic-illness drug programs.

Fintech readiness Strong emphasis on billing and collections for high-cost meds points to upsell prospects in revenue cycle optimization, denial management, and payer negotiation services for specialty medications.

Tech and security Utilizes security and analytics tools (Cloudflare Bot Management, reCAPTCHA, Google Tag Manager) which aligns with selling enhanced data integrity, fraud prevention, and analytics enhancements for healthcare operations.

Growth potential Funding signals and a revenue range of 1M–10M with a scalable, multi-state license footprint indicate room for strategic partnerships with manufacturers, distributors, and HTCs to expand 340B program participation and service offerings.